JP5351889B2 - インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質 - Google Patents

インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質 Download PDF

Info

Publication number
JP5351889B2
JP5351889B2 JP2010512606A JP2010512606A JP5351889B2 JP 5351889 B2 JP5351889 B2 JP 5351889B2 JP 2010512606 A JP2010512606 A JP 2010512606A JP 2010512606 A JP2010512606 A JP 2010512606A JP 5351889 B2 JP5351889 B2 JP 5351889B2
Authority
JP
Japan
Prior art keywords
pas
ifna2b
amino acid
protein
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010512606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010531139A (ja
JP2010531139A5 (enExample
Inventor
スケラ，アメ
シーオボールド，イナ
シェラプシー，マーティン
Original Assignee
テクニシェ ユニバーシタット ミュンヘン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39776993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5351889(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by テクニシェ ユニバーシタット ミュンヘン filed Critical テクニシェ ユニバーシタット ミュンヘン
Publication of JP2010531139A publication Critical patent/JP2010531139A/ja
Publication of JP2010531139A5 publication Critical patent/JP2010531139A5/ja
Application granted granted Critical
Publication of JP5351889B2 publication Critical patent/JP5351889B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
JP2010512606A 2007-06-21 2008-06-20 インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質 Active JP5351889B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07012219 2007-06-21
EP07012219.7 2007-06-21
US7170508P 2008-05-14 2008-05-14
US61/071,705 2008-05-14
PCT/EP2008/005020 WO2008155134A1 (en) 2007-06-21 2008-06-20 Biological active proteins having increased in vivo and/or vitro stability

Publications (3)

Publication Number Publication Date
JP2010531139A JP2010531139A (ja) 2010-09-24
JP2010531139A5 JP2010531139A5 (enExample) 2012-12-06
JP5351889B2 true JP5351889B2 (ja) 2013-11-27

Family

ID=39776993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512606A Active JP5351889B2 (ja) 2007-06-21 2008-06-20 インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質

Country Status (19)

Country Link
US (2) US8563521B2 (enExample)
EP (2) EP2369005B1 (enExample)
JP (1) JP5351889B2 (enExample)
KR (2) KR101701080B1 (enExample)
CN (1) CN101970678B (enExample)
AT (1) ATE502114T1 (enExample)
AU (1) AU2008266448B2 (enExample)
CA (1) CA2691386C (enExample)
CY (1) CY1111491T1 (enExample)
DE (1) DE602008005596D1 (enExample)
DK (2) DK2369005T3 (enExample)
EA (1) EA021222B8 (enExample)
ES (2) ES2422007T3 (enExample)
HR (1) HRP20110368T1 (enExample)
NZ (1) NZ580670A (enExample)
PL (2) PL2173890T3 (enExample)
PT (1) PT2173890E (enExample)
SI (2) SI2173890T1 (enExample)
WO (1) WO2008155134A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091068A1 (ja) * 2018-11-02 2020-05-07 味の素株式会社 融合タンパク質

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
JP2009525946A (ja) 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
JP5351889B2 (ja) 2007-06-21 2013-11-27 テクニシェ ユニバーシタット ミュンヘン インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
HUE054585T2 (hu) 2008-04-29 2021-09-28 Ascendis Pharma Endocrinology Div A/S Pegilezett rekombináns humán növekedési hormon vegyületek
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
CN108530543B (zh) * 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
JP5839597B2 (ja) * 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
DK2440241T3 (en) * 2009-06-08 2017-10-02 Amunix Operating Inc GROWTH HORMON POLYPEPTIDES AND PROCEDURES FOR PREPARING AND USING THEREOF
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
CA2783296C (en) 2009-12-15 2019-01-15 Ascendis Pharma As Growth hormone composition
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
HRP20171291T1 (hr) 2010-02-04 2017-10-20 Morphotek, Inc. Polipeptidi i konjugati klorotoksina i njihove uporabe
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EP4450523A3 (en) * 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN103097403B (zh) 2010-05-11 2017-04-19 弗雷德哈钦森癌症研究中心 氯毒素变体、缀合物及其使用方法
MX338914B (es) * 2010-05-21 2016-05-06 Xl Protein Gmbh Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos.
ES2674567T3 (es) 2010-05-21 2018-07-02 Merrimack Pharmaceuticals, Inc. Proteínas de fusión biespecíficas
US9012403B2 (en) 2010-06-18 2015-04-21 Xiberscience Gmbh Peptides as active agents to stabilize biological barriers
SG187231A1 (en) 2010-07-29 2013-02-28 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
CN113278077A (zh) 2010-11-26 2021-08-20 分子组合公司 设计的与血清白蛋白结合的重复蛋白
IL210093A0 (en) 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
AU2012282875B2 (en) 2011-07-08 2016-04-21 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
CA2843197A1 (en) 2011-07-29 2013-02-07 Eleven Biotherapeutics, Inc. Purified proteins
WO2013024049A1 (en) * 2011-08-12 2013-02-21 Ascendis Pharma A/S Protein carrier-linked prodrugs
EP2741781A1 (en) * 2011-08-12 2014-06-18 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
EP2804623B1 (en) 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
CA2865578C (en) 2012-02-27 2023-01-17 Amunix Operating Inc. Xten conjugate compositions and methods of making same
PL2846836T3 (pl) 2012-05-07 2020-01-31 Allergan, Inc. Sposób leczenia amd u pacjentów opornych na terapię anty- vegf
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc Chimeric clotting factors
EP2867360B1 (en) 2012-06-28 2019-05-08 Molecular Partners AG Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
CN110054699A (zh) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
WO2014026054A2 (en) 2012-08-10 2014-02-13 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
US20140092376A1 (en) * 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (en) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CA2913127A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Methods for screening
TWI674270B (zh) 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
FI3889173T3 (fi) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
CN107693781B (zh) 2013-03-13 2021-11-09 巴扎德制药公司 用于眼部递送的嵌合细胞因子制剂
AU2014230472A1 (en) 2013-03-14 2015-10-01 Medimmune Limited Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
MX2015016567A (es) 2013-06-28 2016-03-31 Biogen Ma Inc Enlazador escindible por trombina con xten y usos del mismo.
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3628324A1 (en) 2013-11-05 2020-04-01 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US20160296600A1 (en) 2013-11-11 2016-10-13 Ascendis Pharma Relaxin Division A/S Relaxin Prodrugs
DE102013113156A1 (de) 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
EP3082848B1 (en) 2013-12-06 2023-10-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
WO2015095553A1 (en) 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
EP3113792B1 (en) 2014-03-05 2018-12-05 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with increased duration of effect
SG11201607642RA (en) 2014-03-24 2016-10-28 Biogen Ma Inc Lyophilized factor ix formulations
EP2937096B1 (en) 2014-04-23 2019-08-21 Julius-Maximilians-Universität Würzburg Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
AP2017009826A0 (en) 2014-09-26 2017-03-31 Bayer Pharma AG Stabilized adrenomedullin derivatives and use thereof
CA2963053C (en) 2014-09-30 2024-01-23 Thena Biotech S.r.l. A fusion protein, a nanoparticle composed by a plurality of monomers of said fusion protein, and uses thereof
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
ES2947818T3 (es) 2014-11-18 2023-08-21 Ascendis Pharma Endocrinology Div A/S Nuevos profármacos poliméricos de la HCh
ES2896971T3 (es) 2014-11-21 2022-02-28 Ascendis Pharma Endocrinology Div A/S Formas de administración de hormona del crecimiento de acción prolongada
JP7075757B2 (ja) 2014-11-21 2022-05-26 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 制御放出および持続的放出のためのｅｌｐ融合タンパク質
WO2016094627A1 (en) 2014-12-10 2016-06-16 S-Aima Holding Company, Llc Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
WO2016130518A2 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
US10478394B2 (en) 2015-03-11 2019-11-19 Wayne State University Compositions and methods to promote wound healing
BR112017020986A2 (pt) 2015-04-02 2018-08-14 Molecular Partners Ag. proteínas de ligação recombinantes e seu uso
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
EP3373954A4 (en) * 2015-11-10 2019-07-03 Proteothera, Inc. PROCESS FOR PREPARING AND CLEANING MATRIX-BINDING FUSION PROTEINS BY ION EXCHANGE CHROMATOGRAPHY
PL3394266T3 (pl) * 2015-12-22 2021-12-13 Xl-Protein Gmbh Kwasy nukleinowe kodujące powtarzalne sekwencje aminokwasowe bogate w reszty proliny i alaniny, które mają sekwencje nukleotydowe o niskiej powtarzalności
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
AU2017205694B2 (en) 2016-01-08 2022-05-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
AU2017205690B2 (en) 2016-01-08 2022-04-28 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with increased NEP stability
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
ES2929347T3 (es) 2016-01-20 2022-11-28 Merz Pharma Gmbh & Co Kgaa Nuevas neurotoxinas clostridiales recombinantes con aumento de la duración del efecto
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
IL317744A (en) 2016-03-01 2025-02-01 Ascendis Pharma Bone Diseases As PTH drug agonists
ES2893838T3 (es) 2016-03-02 2022-02-10 Merz Pharma Gmbh & Co Kgaa Composición que comprende toxina botulínica
US10676517B2 (en) 2016-03-10 2020-06-09 Medimmune Limited Glucagon and GLP-1 co-agonists for the treatment of obesity
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
AU2017260274A1 (en) * 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CN118078956A (zh) 2016-05-06 2024-05-28 免疫新炉有限公司 用于受控和持续释放的elp融合蛋白
EP3484523A1 (en) 2016-07-13 2019-05-22 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
RS64440B1 (sr) 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
FI3518982T3 (fi) 2016-09-29 2025-02-11 Ascendis Pharma Bone Diseases As Säädellysti vapautuvia PTH-yhdisteitä
HRP20230385T1 (hr) 2016-09-29 2023-06-23 Ascendis Pharma Growth Disorders A/S Kombinirana terapija sa cnp agonistima s kontroliranim oslobađanjem
PL3518961T3 (pl) 2016-09-29 2023-08-14 Ascendis Pharma Bone Diseases A/S Związki pth o niskim stosunku wartości maksymalnej do minimalnej
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018112362A1 (en) 2016-12-16 2018-06-21 Biogen Ma Inc. Stabilized proteolytically activated growth differentiation factor 11
WO2018144623A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
EP3596114A2 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
IL320149A (en) 2017-03-16 2025-06-01 Alpine Immune Sciences Inc Pd-l1 variant immunomodulatory proteins and uses thereof
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
WO2018193122A1 (en) 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
EP3641827A1 (en) * 2017-06-21 2020-04-29 XL-protein GmbH Conjugates of protein drugs and p/a peptides
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
KR102727396B1 (ko) 2017-06-21 2024-11-08 재즈 파마슈티칼즈 아일랜드 리미티드 변형된 l-아스파라기나아제
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
BR112020002394A2 (pt) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. moléculas de ácidos nucleicos e usos das mesmas
WO2019074983A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
CA3082076A1 (en) * 2017-11-06 2019-05-09 Thena Biotech S.r.l. Fusion-proteins based on human ferritin and protease-cleavable peptides and their use as chemotherapeutics carriers
EP3483619A1 (en) * 2017-11-13 2019-05-15 Technische Universität München Automated noninvasive determining the sex of an embryo of and the fertility of a bird's egg
JP2021507706A (ja) 2017-12-21 2021-02-25 アムニクス ファーマシューティカルズ， インコーポレイテッド 放出セグメントおよびそれを含む結合組成物
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
AU2019215063B2 (en) 2018-02-01 2025-10-16 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing Factor VIII
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
CN119504973A (zh) 2018-03-28 2025-02-25 阿森迪斯药物肿瘤股份有限公司 Il-2缀合物
CA3093083A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
KR102824112B1 (ko) 2018-03-28 2025-06-24 브리스톨-마이어스 스큅 컴퍼니 인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법
CA3099620A1 (en) 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
AU2019297327A1 (en) 2018-07-03 2021-02-18 Bristol-Myers Squibb Company FGF21 formulations
KR102925832B1 (ko) 2018-08-09 2026-02-11 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2020053206A1 (en) 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases
MX2021003543A (es) 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
CN111040021B (zh) * 2018-10-12 2023-06-02 浙江道尔生物科技有限公司 一种改善生物活性蛋白性质的载体蛋白
CN111153965A (zh) * 2018-11-07 2020-05-15 浙江道尔生物科技有限公司 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
JP2022513626A (ja) 2018-11-26 2022-02-09 ノバルティス アーゲー Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
JP7713886B2 (ja) 2018-11-30 2025-07-28 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
BR112021010047A2 (pt) 2018-12-06 2021-08-24 Bioverativ Therapeutics Inc. Uso de vetores lentivirais expressando o fator ix
US12403182B2 (en) 2019-02-11 2025-09-02 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
EP3923906A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
EP3934625A1 (en) 2019-03-04 2022-01-12 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
US20220323519A1 (en) 2019-04-17 2022-10-13 Codiak Biosciences, Inc. Compositions of exosomes and aav
GB201905810D0 (en) 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
CA3138805A1 (en) 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
EP3986918A1 (en) 2019-06-18 2022-04-27 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
AU2020295721B2 (en) 2019-06-21 2025-04-03 Ascendis Pharma A/S Conjugates of π-electron-pair-donating heteroaromatic nitrogen-comprising compounds
US20220304993A1 (en) 2019-06-21 2022-09-29 Ascendis Pharma A/S Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
AU2020296297B2 (en) 2019-06-21 2025-06-12 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
EP4021479A2 (en) 2019-08-27 2022-07-06 Tonix Pharma Limited Modified tff2 polypeptides
US12290603B2 (en) 2019-09-27 2025-05-06 Duke University Tabletization of peptide self-assemblies and methods of making and using the same
EP4034237A1 (en) 2019-09-27 2022-08-03 Volution Immuno Pharmaceuticals SA Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
IL294327A (en) 2020-01-03 2022-08-01 Ascendis Pharma As Conjugates undergoing intramolecular rearrangements
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
CN115003320A (zh) 2020-01-13 2022-09-02 阿森迪斯药物骨疾病股份有限公司 甲状旁腺功能减退的治疗
WO2021226551A1 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins and methods of use thereof
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
CN116917482A (zh) 2020-07-30 2023-10-20 银溪制药股份有限公司 嵌合蛋白和治疗中枢神经系统疾病的方法
EP4192508A1 (en) 2020-08-05 2023-06-14 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
CA3189715A1 (en) 2020-08-28 2022-03-03 Ascendis Pharma Oncology Division A/S Glycosylated il-2 proteins and uses thereof
AR123581A1 (es) 2020-09-23 2022-12-21 Ablevia Biotech Gmbh Compuesto para el secuestro de anticuerpos anti peg no deseables en un paciente
EP4217004A1 (en) 2020-09-28 2023-08-02 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
EP4222176A4 (en) 2020-09-30 2024-02-28 Beijing QL Biopharmaceutical Co., Ltd. POLYPEPTIDE CONJUGATES AND METHODS OF USE
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
US20240018265A1 (en) 2020-12-11 2024-01-18 Friedrich Miescher Institute For Biomedical Research Hdac6 binding proteins and their anti-viral use
IL303816A (en) 2020-12-22 2023-08-01 Xl Protein Gmbh Antibodies specific for structurally disordered sequences
KR20230164709A (ko) 2021-04-01 2023-12-04 아센디스 파마 에이에스 염증 유발 질환을 치료하기 위한 지속형 성장 호르몬의 용도
US20240238427A1 (en) 2021-04-14 2024-07-18 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4337668A4 (en) * 2021-05-14 2025-08-13 Antlia Bioscience Inc MODIFIED B-TYPE NATRIURETIC PEPTIDE
TW202313974A (zh) 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 用於治療肝病之組合療法
JP2024534123A (ja) 2021-08-23 2024-09-18 バイオベラティブ セラピューティクス インコーポレイテッド バキュロウイルス発現システム
EP4404951A1 (en) 2021-09-22 2024-07-31 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
CA3236278A1 (en) 2021-12-13 2023-06-22 Kennett Sprogoe Effective doses of cnp conjugates
KR20240163717A (ko) 2022-03-30 2024-11-19 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩티드 접합체의 액체 약학 조성물 및 그의 사용 방법
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
KR20250058784A (ko) * 2022-08-05 2025-04-30 스테이드슨 바이오팔마 아이엔씨. 마스킹 폴리펩티드, 활성화 가능한 신규의 프로드럭 및 이의 사용 방법
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo
CN120752051A (zh) 2022-11-02 2025-10-03 阿森迪斯药物骨疾病股份有限公司 包含两种pth化合物的pth治疗方案
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
JP2026504449A (ja) 2023-02-02 2026-02-05 シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッド Ｉｇｆ－１キメラタンパク質を使用する治療方法
JP2026510974A (ja) 2023-03-20 2026-04-10 アセンディス ファーマ グロース ディスオーダーズ エー／エス 軟骨形成不全症のヒト対象における胸腰椎奇形の治療の方法
WO2025030053A1 (en) 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
CN121752256A (zh) 2023-09-01 2026-03-27 诺沃阿克有限责任公司 具有核酸负载物和可电离脂质的脂质纳米颗粒
IL326658A (en) 2023-09-04 2026-04-01 Ascendis Pharma Bone Diseases As PTH treatment in chronic kidney disease
WO2025088193A1 (en) 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for efficient recombinant production of polypeptides
WO2025088192A1 (en) 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for the coupling of di(alkyl)amines to polypeptides
WO2025233381A1 (en) 2024-05-07 2025-11-13 Technische Universität München, in Vertretung des Freistaates Bayern Enzymes that eliminate pyrimidine and/or purine nucleosides for treating cancer
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
AU2001267337A1 (en) 2000-06-30 2002-01-14 Maxygen Aps Peptide extended glycosylated polypeptides
NZ556726A (en) 2005-01-25 2011-04-29 Cell Therapeutics Inc Conjugates of biologically active proteins having a modified in vivo half-life
DE602006014126D1 (de) * 2005-04-20 2010-06-17 Viromed Co Ltd Zusammensetzungen und verfahren zur trennung von fusionsproteinen
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
DK2402754T4 (da) 2006-03-06 2023-08-28 Amunix Operating Inc Ustrukturerede rekombinante polymerer og anvendelser deraf
JP5351889B2 (ja) 2007-06-21 2013-11-27 テクニシェ ユニバーシタット ミュンヘン インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091068A1 (ja) * 2018-11-02 2020-05-07 味の素株式会社 融合タンパク質

Also Published As

Publication number Publication date
US20140050693A1 (en) 2014-02-20
US20100292130A1 (en) 2010-11-18
PL2173890T3 (pl) 2011-07-29
EP2173890B1 (en) 2011-03-16
PL2369005T3 (pl) 2013-10-31
KR101631323B1 (ko) 2016-06-17
US9260494B2 (en) 2016-02-16
CN101970678B (zh) 2014-08-20
JP2010531139A (ja) 2010-09-24
CY1111491T1 (el) 2015-08-05
CA2691386C (en) 2014-12-23
EA021222B8 (ru) 2015-11-30
AU2008266448B2 (en) 2013-06-13
EP2369005A1 (en) 2011-09-28
EP2173890A1 (en) 2010-04-14
ES2422007T3 (es) 2013-09-06
EA201000040A1 (ru) 2010-06-30
AU2008266448A1 (en) 2008-12-24
EP2369005B1 (en) 2013-04-03
PT2173890E (pt) 2011-05-06
ATE502114T1 (de) 2011-04-15
DK2369005T3 (da) 2013-06-24
SI2173890T1 (sl) 2011-06-30
DK2173890T3 (da) 2011-06-27
KR101701080B1 (ko) 2017-01-31
CN101970678A (zh) 2011-02-09
US8563521B2 (en) 2013-10-22
KR20150092355A (ko) 2015-08-12
WO2008155134A1 (en) 2008-12-24
SI2369005T1 (sl) 2013-09-30
HK1156980A1 (en) 2012-06-22
NZ580670A (en) 2011-09-30
DE602008005596D1 (de) 2011-04-28
HRP20110368T1 (hr) 2011-06-30
ES2362386T3 (es) 2011-07-04
EA021222B1 (ru) 2015-05-29
CA2691386A1 (en) 2008-12-24
KR20100044732A (ko) 2010-04-30

Similar Documents

Publication Publication Date Title
JP2010531139A (ja) インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
JP5828889B2 (ja) プロリン／アラニンランダムコイルポリペプチドの生合成およびその使用
AU2017273743B2 (en) Serum albumin-binding fibronectin type III domains
US20100034804A1 (en) Mutants of streptokinase and their covalently modified forms
JP7703541B2 (ja) 血清アルブミン結合性フィブロネクチンｉｉｉ型ドメインおよびその使用
AU2013203326B2 (en) Biological active proteins having increased in vivo and/or in vitro stability
HK1156980B (en) Biological active proteins having increased in vivo and/or vitro stability
CN116948002A (zh) 一种肽及其复合物
HK40006593A (en) Serum albumin-binding fibronectin type iii domains
HK1219902B (zh) 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途
HK40006036B (en) Serum albumin-binding fibronectin type iii domains
HK40006036A (en) Serum albumin-binding fibronectin type iii domains

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121016

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20121016

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20121024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130220

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20130425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130515

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130823

R150 Certificate of patent or registration of utility model

Ref document number: 5351889

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250